Search

Your search keyword '"Siraj, M"' showing total 207 results

Search Constraints

Start Over You searched for: Author "Siraj, M" Remove constraint Author: "Siraj, M" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
207 results on '"Siraj, M"'

Search Results

1. Supplementary Figure from The Genomics of Colorectal Cancer in Populations with African and European Ancestry

2. Data from The Genomics of Colorectal Cancer in Populations with African and European Ancestry

3. Abstract 3488: Truncated FGFR2 - a clinically actionable oncogene in multiple cancers

4. Data from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

5. Data from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

6. Data from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

7. Supplementary Methods from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

8. Supplementary Table S3 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

9. Supplementary Table S2 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

10. Supplementary Figure S2 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

11. Supplementary Methods, Figure Legends, Table Legend from EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

12. Data from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

13. Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

14. Data from EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

15. Supplementary Table S1A - S1B from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

16. Supplementary Figures S1 - S10 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

17. Supplementary Methods, Figure Legends, Table Legends from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

18. Data from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

19. Supplementary Figures 1 - 6, Table 1 from EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

20. Data from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

21. Supplementary Figures 1 - 3 from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

22. Supplementary Methods, Figures 1 - 5, Tables 1 - 5 from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

23. Supplementary Tables S1 - S3 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

24. Figure S1, Figure S2, Table S1 from Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

25. Supplemental table 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

26. Table S1 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

27. Supplemental Data from Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

28. Supplemental methods from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

29. Supplemental Tables and Figures from Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

30. Figure S3 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

31. Supplemental figure legend from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

32. Supplemental figure 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

33. Supplementary Figure from The Genomics of Colorectal Cancer in Populations with African and European Ancestry

34. Data from The Genomics of Colorectal Cancer in Populations with African and European Ancestry

35. Supplementary Methods, Figures 1 - 5, Tables 1 - 5 from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

36. Supplementary Methods, Figure Legends, Table Legends from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

37. Supplementary Table S3 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

38. Data from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

39. Supplementary Figures 1 - 3 from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

40. Supplementary Tables S1 - S3 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

41. Supplementary Figure S3 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

42. Supplementary Methods from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

43. Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

44. Supplementary Figures S1 - S10 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

45. Supplementary Figures 1 - 6, Table 1 from EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

46. Supplementary Table S3 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

47. Supplementary Methods, Figure Legends, Table Legend from EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

48. Data from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

49. Supplementary Table S1A - S1B from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

50. Figure S4 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

Catalog

Books, media, physical & digital resources